Myoclonic Epilepsy Beginning in Infancy or Early Childhood 

  • Author: Michael C Kruer, MD; Chief Editor: Amy Kao, MD   more...
 
Updated: Dec 8, 2011
 

Background

Myoclonic seizures are characterized by rapid, jerklike movements that can affect the face, limbs, or axial musculature. Most families are familiar with hypnic jerks; that is, a sudden jerk that jolts one awake while falling asleep. In contrast to sleep-related myoclonus, myoclonic seizures occur during wakefulness and are associated with abnormal cortical discharges on EEG. Myoclonic seizures can occur in isolation or as part of a mixed-generalized epilepsy syndrome. Myoclonic epilepsies with onset in infancy and childhood are clinically and etiologically heterogeneous but, as a group, may be refractory to treatment.

The overall prognosis associated with myoclonic epilepsy in childhood depends on the underlying etiology. Identification of a distinct epilepsy syndrome may enable more accurate prognostication (see Etiology).

Clinical features can aid in the differentiation of myoclonic epilepsies from other forms of epilepsy and paroxysmal movements of childhood (see Clinical).

EEG is required to distinguish myoclonic seizures from nonictal causes of myoclonus, which can arise from lesions of the cortex, brainstem, spinal cord, or even peripheral nerve (see Workup).

The mainstays of therapy for myoclonic seizures are valproic acid (sodium valproate) and benzodiazepines (see Treatment). Some anticonvulsants may precipitate myoclonic seizures in predisposed individuals.

Next

Pathophysiology

Myoclonic seizures are generally the product of hypersynchronous, generalized cortical discharges. These discharges arise from hyperexcitable neuronal networks.

Previous
Next

Etiology

Seizures associated with early myoclonic encephalopathy can be due to a number of etiologies. The International League Against Epilepsy (ILAE) has recently revised concepts and terminology related to the classification and description of seizures.[1] This report emphasized that concepts related to the characterization of seizures, their etiologies, and meaningful electroclinical syndromes are evolving. Practically speaking, myoclonic seizures can be grouped into the following categories (myoclonic absences, myoclonic tonic seizures, and myoclonic clonic seizure types are not discussed here):

  • Early infantile epileptic encephalopathies[2] - This includes early myoclonic encephalopathy (EME) and early infantile epileptic encephalopathy (EIEE). These are severe disorders with a grave prognosis. Causes of early infantile epileptic encephalopathies include brain malformations, inborn errors of metabolism, and neurogenetic disorders.
  • Myoclonic epilepsy occurring as part of a mixed generalized epilepsy syndrome - This includes Doose syndrome (myoclonic-atonic epilepsy),[3] Dravet syndrome (severe myoclonic epilepsy of infancy),[4] and Lennox-Gastaut syndrome,[5] as well as other syndromes that feature several kinds of generalized seizures. Causes may include cortical malformation and ion channel mutations, such as SCN1A mutations.
  • Nonprogressive myoclonic epilepsies - This group of disorders overall has a more favorable prognosis and includes benign neonatal myoclonic epilepsy, familial myoclonic epilepsy, and autosomal dominant cortical myoclonus and epilepsy, among others. However, nonprogressive myoclonic encephalopathies may also occur, with a more guarded prognosis. These disorders are usually genetically determined conditions.
  • Progressive myoclonic epilepsies[6] - In this class of myoclonic epilepsies, seizures occur in the context of an underlying neurodegenerative disorder. Representative diseases include Unverricht-Lundborg disease, Lafora body disease, myoclonic epilepsy with ragged red fibers (MERRF), the neuronal ceroid lipofuscinoses, sialidosis, and dentate-rubral-pallidoluysian atrophy (DRPLA). Myoclonus occurring in the context of these disorders may be stimulus-sensitive or action-induced.

Some children may not be readily classifiable in any of the above categories.

Across subtypes of childhood myoclonic epilepsy, many patients have an underlying genetic cause for their seizures. In some cases, myoclonic seizures may be a prominent feature of a syndrome with wider central nervous system and systemic manifestations, such as is seen in mitochondrial diseases (ie, MERRF or Alper syndrome [POLG1 mutations]). However, despite advances in identifying causes of epilepsy, for most cases of infantile and early childhood myoclonic epilepsy, no clear etiology will be found despite an appropriate workup.

Previous
Next

Epidemiology

The incidence of myoclonic epilepsy is approximately 1 case in 40,000 children. Typically, the onset of these disorders is during the first 3 years of life. There are no known racial or sexual differences in the overall frequency of myoclonic epilepsies, although there may be differences in prevalence among specific populations for certain forms of myoclonic epilepsy (ie, Baltic epilepsy).

Previous
Next

Prognosis

The prognosis depends heavily on the underlying etiology and the epilepsy syndrome. Patients with a benign syndrome typically respond well to medication and may outgrow their epilepsy. In other myoclonic epilepsy syndromes, the prognosis is usually less favorable.

Death in patients with myoclonic epilepsy may be related to the underlying disorder but is unlikely to be due to the myoclonic seizures themselves. Aspiration pneumonia is more common in this population and may result in frequent hospitalizations.

Previous
Next

Patient Education

For patient education information, see the Brain and Nervous System Center, as well as Epilepsy.

Previous
 
 
Contributor Information and Disclosures
Author

Michael C Kruer, MD  Assistant Professor, Departments of Pediatrics and Neurosciences, Sanford School of Medicine, University of South Dakota; Physician in Pediatric Neurology and Neurogenetics, Sanford Children's Specialty Clinic, Sanford Children's Hospital

Michael C Kruer, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Neurology, American Academy of Pediatrics, American Society of Human Genetics, Child Neurology Society, and Society for Neuroscience

Disclosure: EMD/Serono Grant/research funds Grant PI

Coauthor(s)

Raj D Sheth, MD  Professor, Mayo College of Medicine; Chief, Division of Pediatric Neurology, Nemours Children's Clinic

Raj D Sheth, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, American Neurological Association, and Child Neurology Society

Disclosure: Nothing to disclose.

Chief Editor

Amy Kao, MD  Attending Neurologist, Children's National Medical Center

Amy Kao, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, and Child Neurology Society

Disclosure: Nothing to disclose.

Additional Contributors

James J Riviello Jr, MD George Peterkin Endowed Chair in Pediatrics, Professor of Pediatrics, Section of Neurology and Developmental Neuroscience, Professor of Neurology, Peter Kellaway Section of Neurophysiology, Baylor College of Medicine; Chief of Neurophysiology, Director of the Epilepsy and Neurophysiology Program, Texas Children's Hospital

James J Riviello Jr, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Up To Date Royalty Section Editor

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

References
  1. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. Apr 2010;51(4):676-85. [Medline].

  2. Djukic A, Lado FA, Shinnar S, Moshé SL. Are early myoclonic encephalopathy (EME) and the Ohtahara syndrome (EIEE) independent of each other?. Epilepsy Res. Aug 2006;70 Suppl 1:S68-76. [Medline].

  3. Kelley SA, Kossoff EH. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress. Dev Med Child Neurol. Nov 2010;52(11):988-93. [Medline].

  4. Dravet C. The core Dravet syndrome phenotype. Epilepsia. Apr 2011;52 Suppl 2:3-9. [Medline].

  5. Michoulas A, Farrell K. Medical management of Lennox-Gastaut syndrome. CNS Drugs. May 1 2010;24(5):363-74. [Medline].

  6. Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol. Apr 2005;4(4):239-48. [Medline].

  7. Cohen BH, Chinnery PF, Copeland WC. POLG-Related Disorders. In: Pagon RA, Bird TD, Dolan CR, Stephens K, eds. GeneReviews [Internet]. University of Washington, Seattle; 1993-2010 Mar 16.

  8. Crompton DE, Berkovic SF. The borderland of epilepsy: clinical and molecular features of phenomena that mimic epileptic seizures. Lancet Neurol. Apr 2009;8(4):370-81. [Medline].

  9. Korff CM, Nordli DR Jr. Epilepsy syndromes in infancy. Pediatr Neurol. Apr 2006;34(4):253-63. [Medline].

  10. Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. Jan 1998;29(2):147-54. [Medline].

  11. Andrade DM, Hamani C, Minassian BA. Treatment options for epileptic myoclonus and epilepsy syndromes associated with myoclonus. Expert Opin Pharmacother. Jul 2009;10(10):1549-60. [Medline].

  12. Wheless JW, Sankar R. Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia. 2003;44 Suppl 11:27-37. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.